Skip to main content
SpringerLink
Log in

Should somatostatin or gabexate be given for prophylaxis of pancreatitis in patients undergoing ERCP?

  • Practice Point
  • Published:

From Nature Clinical Practice Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Freeman ML and Guda NM (2004) Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 59: 845–864

    Article  Google Scholar 

  2. Freeman ML et al. (2001) Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 54: 425–434

    Article  CAS  Google Scholar 

  3. Manes G et al. (2007) Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest Endosc 65: 982–987

    Article  Google Scholar 

  4. Poon RT et al. (2003) Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut 52: 1768–1773

    Article  CAS  Google Scholar 

  5. Singh P et al. (2004) Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 60: 544–550

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. University of Pittsburgh and University of Pittsburgh Medical Center, PUH, Mezzanine 2, C Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA papachristoug@dom.pitt.edu

Authors and Affiliations

  1. GI Papachristou is an Assistant Professor of Medicine at the University of Pittsburgh, Pittsburgh, PA, USA.,

    Georgios I Papachristou

Authors
  1. Georgios I Papachristou
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papachristou, G. Should somatostatin or gabexate be given for prophylaxis of pancreatitis in patients undergoing ERCP?. Nat Rev Gastroenterol Hepatol 5, 14–15 (2008). https://doi.org/10.1038/ncpgasthep0996

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0996

  • Springer Nature Limited

Search

Navigation